IN
INCR.US InterCure Ltd.
- Market cap
- USD 49.2M
- P/E
- -
- P/B
- 0.46x
- ROE
- -17.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is INCR.US undervalued?
Graham numberThe Graham number of InterCure Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InterCure Ltd. fundamental analysis
No fundamental analysis for InterCure Ltd. yet.
InterCure Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Full company profileInterCure Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InterCure Ltd. annual financial statements (ILS; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 0.00 | 8.93M | 65.0M | 220M | 389M | 356M | 239M | 270M | 280M |
| Gross Profit | - | 0.00 | - | 1.48M | 32.0M | 91.1M | 155M | 105M | 30.2M | 33.2M | 958K |
| Operating Income | 1.20M | -3.98M | -10.6M | -3.42M | -38.4M | 28.2M | 50.6M | -41.6M | -67.2M | 6.73M | -65.9M |
| EBITDA | -1.07M | -1.15M | -10.1M | -3.77M | -34.5M | 31.2M | 70.2M | -23.9M | -51.3M | -7.29M | -139M |
| Net Income | 265K | -5.26M | -12.8M | -5.89M | -37.2M | 4.69M | 44.8M | -62.0M | -67.8M | -35.7M | -68.0M |
| EPS | 0.10 | -1.54 | -3.11 | -1.26 | -7.33 | 0.57 | 4.94 | -6.80 | -7.10 | -3.14 | -6.71 |
| Balance Sheet | |||||||||||
| Total Assets | 27.7M | 23.9M | 35.9M | 282M | 326M | 686M | 958M | 787M | 763M | 691M | 691M |
| Total Liabilities | 3.67M | 3.27M | 16.3M | 26.0M | 34.2M | 227M | 437M | 330M | 365M | 294M | 294M |
| Shareholders' Equity | 24.1M | 20.7M | 19.7M | 256M | 275M | 448M | 501M | 455M | 397M | 397M | 397M |
| Cash & Short-term Investments | 3.25M | 2.44M | 3.66M | 27.5M | 38.3M | 197M | 233M | 101M | 78.7M | 46.7M | 46.7M |
| Total Debt | 2.39M | 2.94M | 12.8M | 17.1M | 6.68M | 109M | 255M | 196M | 211M | 183M | 183M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.17M | -921K | -1.49M | -4.01M | 7.80M | 25.0M | 51.3M | -53.6M | -66.9M | 16.8M | 67.4M |
| Capital Expenditure | 7.69K | 93.0K | 93.0K | 1.00K | 20.8M | 14.0M | 19.7M | 2.62M | 4.38M | 3.55M | 14.2M |
| Free Cash Flow | -1.18M | -921K | -1.58M | -4.01M | -13.0M | 11.0M | 31.5M | -56.3M | -71.3M | 13.3M | 53.2M |
| Ratios | |||||||||||
| ROE | 1.1% | -25.4% | -65.1% | -2.3% | -13.6% | 1.0% | 8.9% | -13.6% | -17.1% | -9.0% | -17.2% |
| ROA | 1.0% | -22.0% | -35.6% | -2.1% | -11.4% | 0.7% | 4.7% | -7.9% | -8.9% | -5.2% | -9.8% |
| Net Profit Margin | - | - | - | -66.0% | -57.2% | 2.1% | 11.5% | -17.4% | -28.4% | -13.2% | -24.3% |
| Debt to Equity | 0.10x | 0.14x | 0.65x | 0.07x | 0.02x | 0.24x | 0.51x | 0.43x | 0.53x | 0.46x | 0.46x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InterCure Ltd. dividends
InterCure Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Aug 24, 2026.
Who owns InterCure Ltd.
- Insiders 34.89%
- Institutions 0.84%
- Public & others 64.27%
- Shares outstanding 13.0M
- Free float 6.65M
Top funds holding INCR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 4.07K | 0.03% | 0.00% | Aug 2026 |
InterCure Ltd. company profile
- Company name
- InterCure Ltd.
- Ticker
- INCR.US
- ISIN
- IL0011063760
- Exchange
- USA Stocks
- Listed since
- Nov 7, 2014
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 285
- Fiscal year end
- December
- Address
- 85 Medinat ha-Yehudim Street, Herzliya, Israel, 4676670
- Phone
- 972 7 746 05012
- Website
- intercure.co
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
InterCure Ltd. management
6- Mr. Alexander RabinovichFounder, CEO & Chairman · born 1971
- Mr. Amos CohenChief Financial Officer · born 1979
- Ms. Einat ZehaviChief Executive Officer of Retail
- Mr. Omer LayaniChief Technology Officer
- Mr. Yarin LidorHead of Marketing
- Mr. Dean SimhonHead of Supply Chain